** Shares of drugmaker Regeneron REGN.O rise 3.5% to $591.78
** U.S. FDA has extended the target action dates for two applications of the high-dose version of REGN's eye disease drug, Eylea, to the fourth quarter
** Earlier this month, REGN said it expected a delay due to an inspection at contract manufacturer Catalent's site, which was acquired by Danish drugmaker Novo Nordisk NOVOb.CO
** This outcome is an improvement on expectations, with investors likely anticipating longer timelines for regulatory decisions - BMO Capital Markets
** This development is also positive for Scholar Rock SRRK.O, which produces its drug for a rare neuromuscular disease at the affected facilities - BMO
** Shares of SRRK, which is expecting FDA's decision on the experimental drug for spinal muscular atrophy by September 22, gain 12.90% to $34.01
** REGN shares down 17%, while SRRK stock fell 21%, YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。